What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

Structure Therapeutics' lead product candidate is GSBR-1290, a highly selective oral GLP-1 receptor agonist, which is being evaluated in multiple mid-stage studies for treating healthy overweight or obese individuals. The Zacks Consensus Estimate is currently pegged at a loss of 23 cents per share. Let's see how things might have shaped up for the upcoming quarterly release. The company plans to file an investigational new drug application to the FDA in the third quarter of 2024 to begin the phase IIb obesi ...